/**
 * BCI topic CONTENT
 * ────────────────────
 * All content for the Brain-Computer Interface topic page.
 * Edit this file to update text, topics, stats, sections.
 * Does NOT affect other topic pages.
 */

export const bciContent = {
  name: 'Brain-Computer Interfaces',
  slug: 'bci',
  tagline: 'Neuralink, neurochips, AI neural decoding & the neurotechnological era',
  description:
    'From Neuralink human trials and AI-powered speech decoding to non-invasive EEG headsets and bidirectional closed-loop systems — explore the technology connecting brains to machines.',
  icon: '🧠',
  gradient: 'linear-gradient(135deg, #0ea5e9 0%, #6366f1 50%, #a855f7 100%)',
  accentColor: '#0ea5e9',
  accentColor2: '#38bdf8',

  // ── Hero Stats ──────────────────────────────
  stats: [
    { value: '$3.2B', label: 'BCI market 2026' },
    { value: '21', label: 'Neuralink implants across 4 nations' },
    { value: '$1.6B', label: 'VC funding raised 2025–2026' },
    { value: '62 WPM', label: 'Speech decoding record' },
  ],

  // ── Section 1: Market Overview ──────────────
  marketOverview: {
    title: 'Brain-Computer Interface Market Overview & Growth Forecast',
    subtitle: 'A $3.2 billion market in 2026, projected to reach $6–12 billion by 2030 at 15–18% CAGR — bifurcating into clinical invasive BCIs and consumer non-invasive neurotechnology.',
    marketSize: [
      { segment: 'Clinical Invasive BCI', year2025: '$1.2B', year2030: '$4.5B', cagr: '18%' },
      { segment: 'Non-Invasive Consumer EEG', year2025: '$0.8B', year2030: '$3.2B', cagr: '22%' },
      { segment: 'Deep Brain Stimulation', year2025: '$1.4B', year2030: '$2.8B', cagr: '12%' },
      { segment: 'Total BCI Market', year2025: '$2.8B', year2030: '$8.5B', cagr: '17%' },
    ],
    keyDrivers: [
      { title: 'Clinical Trial Momentum', desc: 'Multiple companies simultaneously enrolling patients across 4+ countries. Synchron preparing pivotal study for FDA PMA by 2028.' },
      { title: 'AI + BCI Convergence', desc: 'LLM integration enabling fluent natural language from sparse neural signals. Transformer-based decoders achieving 62 WPM speech restoration.' },
      { title: 'Record VC Investment', desc: '$1.6B+ raised in 2025–2026 YTD. Neuralink $650M, Synchron $200M, Merge Labs $252M, Science Corp $230M.' },
      { title: 'Consumer Neurotech Maturation', desc: 'EMOTIV, Neurable expanding market for productivity, gaming, and accessibility. EEG headsets achieving clinically meaningful signal resolution.' },
    ],
  },

  // ── Section 2: Key Players & Devices ────────
  keyPlayers: {
    title: 'BCI Key Players & Devices: 2026 Landscape',
    subtitle: 'Six companies in human trials. China approved the world\'s first commercial invasive BCI. The race between invasive precision and non-invasive accessibility is on.',
    devices: [
      { name: 'Neuralink N1 Implant (Telepathy)', company: 'Neuralink', type: 'Intracortical', electrodes: '1,024', status: 'IDE', stage: 'Investigational', desc: '1,024 electrode threads thinner than human hair. 21 patients implanted across 4 nations. Cursor control, working toward speech decoding.' },
      { name: 'Neuralink Blindsight', company: 'Neuralink', type: 'Intracortical', electrodes: '1,024', status: 'Breakthrough', stage: 'Investigational', desc: 'Cortical visual prosthesis. First-in-human implant in 2026. Aims to restore vision to blind patients.' },
      { name: 'Stentrode', company: 'Synchron', type: 'Endovascular', electrodes: '16', status: 'Breakthrough', stage: 'Investigational', desc: 'Inserted via blood vessels — no open brain surgery. Completed US feasibility trial, preparing pivotal study for FDA PMA by 2028.' },
      { name: 'Connexus Direct Data Interface', company: 'Paradromics', type: 'Intracortical', electrodes: '1,684', status: 'IDE', stage: 'Investigational', desc: 'High-bandwidth speech restoration BCI. Connect-One first chronic implant opened at University of Michigan, February 2026.' },
      { name: 'Layer 7 Cortical Interface', company: 'Precision Neuroscience', type: 'Epi-cortical', electrodes: '1,024', status: '510(k) Cleared', stage: 'Investigational', desc: 'Sits on top of brain without penetrating tissue. FDA 510(k) clearance granted. Moving toward chronic wireless implant study.' },
      { name: 'NEO BCI', company: 'Neuracle (China)', type: 'Epi-cortical', electrodes: '8', status: 'Commercial', stage: 'Approved', desc: 'World\'s first approved invasive BCI product beyond clinical trials. Approved in China for spinal cord injury paralysis. Incorporated into health insurance.' },
    ],
  },

  // ── Section 3: Invasive vs Non-Invasive ─────
  invasiveVsNon: {
    title: 'Invasive vs Non-Invasive BCIs: Trade-offs & Applications',
    subtitle: 'Invasive BCIs offer highest fidelity with surgical risk. Non-invasive BCIs offer safety with lower resolution. AI is closing the gap.',
    comparison: [
      { feature: 'Signal Quality', invasive: 'High (direct neural recording)', nonInvasive: 'Moderate (attenuated by skull)' },
      { feature: 'Spatial Resolution', invasive: 'Single neuron level', nonInvasive: 'Centimeter scale' },
      { feature: 'Surgical Risk', invasive: 'Yes — craniotomy or endovascular', nonInvasive: 'None' },
      { feature: 'Regulatory Path', invasive: 'FDA IDE / PMA (years)', nonInvasive: 'Consumer product (months)' },
      { feature: 'Current Applications', invasive: 'Paralysis, ALS, blindness', nonInvasive: 'Gaming, focus, meditation' },
      { feature: 'Cost', invasive: '$50K–$200K+', nonInvasive: '$200–$2,000' },
    ],
    invasiveApproaches: [
      { name: 'Intracortical', desc: 'Microelectrode arrays directly penetrating brain tissue. Highest signal fidelity. Risk of glial scarring and signal degradation over time.' },
      { name: 'Epi-cortical', desc: 'Electrode arrays resting on brain surface without penetration. Lower risk than intracortical. Precision Neuroscience approach.' },
      { name: 'Endovascular', desc: 'Stent-like device inserted through blood vessels. No open brain surgery. Synchron Stentrode approach.' },
    ],
    nonInvasiveApproaches: [
      { name: 'EEG', desc: 'Electroencephalography via scalp electrodes. Most common non-invasive BCI. Dry electrodes, fabric-based wearable, and e-tattoo sensors advancing.' },
      { name: 'fNIRS', desc: 'Functional near-infrared spectroscopy. Measures blood oxygenation. Combining with EEG for multimodal signal fusion improves accuracy.' },
      { name: 'tFUS', desc: 'Transcranial focused ultrasound. Emerging modality for both reading and stimulating brain activity non-invasively with high spatial precision.' },
    ],
  },

  // ── Section 4: AI + BCI Convergence ─────────
  aiConvergence: {
    title: 'AI + BCI Convergence: Neural Decoding Revolution',
    subtitle: 'Transformer-based neural decoders and LLM integration are transforming sparse brain signals into fluent speech, motor commands, and digital actions.',
    breakthroughs: [
      { title: 'Speech Decoding at 62 WPM', desc: 'Stanford/BrainGate achieved 62 words per minute — approaching natural speech rate of ~150 WPM. UCSF team decoded full sentences from a paralyzed ALS patient.' },
      { title: 'LLM Integration for Fluent Language', desc: 'Large language models retrained on neural signal corpora enable BCI systems to decode intended speech with accuracy levels making real-world deployment practical.' },
      { title: 'Deep Learning Neural Decoders', desc: 'Deep neural networks dramatically improved signal processing. Reduced calibration burden on end users. Real-time neural signal interpretation at low power via edge AI processors.' },
      { title: 'Handwriting Decoding', desc: 'BrainGate decoded imagined handwriting at 90 characters per minute with 94% accuracy. Transformer models translating neural pen trajectories to text.' },
    ],
  },

  // ── Section 5: Clinical Applications ────────
  clinicalApps: {
    title: 'Clinical Applications: Restoring Lost Functions',
    subtitle: 'BCIs are restoring communication, movement, and vision for patients with paralysis, ALS, spinal cord injury, epilepsy, and Parkinson\'s disease.',
    applications: [
      { name: 'Communication Restoration', desc: 'Speech BCIs decode intended speech from motor cortex. ALS and locked-in syndrome patients typing, browsing, and communicating at approaching natural speeds.', patients: '30+' },
      { name: 'Motor Restoration', desc: 'Intracortical BCIs enable paralyzed individuals to control computer cursors, robotic arms, and digital devices. First patient Noland Arbaugh controlling cursor with thoughts.', patients: '21+' },
      { name: 'Visual Prosthetics', desc: 'Cortical implants for blindness restoration. Neuralink Blindsight first-in-human implant in 2026. Science Corporation PRIMA retinal implant seeking CE mark.', patients: '5+' },
      { name: 'Seizure Prevention', desc: 'NeuroPace RNS: FDA-approved closed-loop system detecting seizure onset and delivering electrical stimulation. Over 4,000 patients implanted.', patients: '4,000+' },
      { name: 'Parkinson\'s DBS', desc: 'Commercial deep brain stimulation (Medtronic, Abbott, Boston Scientific) — largest BCI segment by revenue. Shift from open-loop to closed-loop systems.', patients: '150,000+' },
      { name: 'Depression Treatment', desc: 'Closed-loop DBS for treatment-resistant depression. UCSF study showed remarkable sustained symptom relief by detecting and stimulating on neural biomarkers.', patients: '10+' },
    ],
  },

  // ── Section 6: Consumer Neurotech ───────────
  consumerNeurotech: {
    title: 'Consumer Neurotech: Non-Invasive BCI Goes Mainstream',
    subtitle: 'EEG headsets for gaming, focus monitoring, meditation, and accessibility — achieving clinically meaningful signal resolution without surgery.',
    companies: [
      { name: 'EMOTIV', product: 'EPOC X / Insight', desc: '14-channel EEG headsets for research, education, and brain-computer interface development. Used in 100+ countries.' },
      { name: 'Neurable', product: 'MW70 Headphones', desc: 'EEG-integrated headphones for focus tracking and productivity. First consumer BCI product shipping at scale.' },
      { name: 'Muse', product: 'Muse S / 2', desc: 'Meditation and sleep tracking via EEG. Real-time feedback on brain activity during meditation sessions.' },
      { name: 'Neurosity', product: 'Crown', desc: 'Brainwave monitoring for focus and flow state. Developer SDK for building BCI applications.' },
    ],
    applications: [
      'Gaming: Brain-controlled interfaces and neurofeedback-enhanced gameplay',
      'Productivity: Focus monitoring, flow state detection, attention optimization',
      'Mental Health: Meditation guidance, anxiety tracking, neurofeedback therapy',
      'Accessibility: Non-verbal communication, assistive device control',
      'Education: Attention monitoring, learning optimization, cognitive load assessment',
    ],
  },

  // ── Section 7: Investment & Funding ─────────
  investment: {
    title: 'BCI Investment & Funding Landscape',
    subtitle: '$1.6B+ raised in 2025–2026 YTD. The market is bifurcating: clinical-stage invasive BCIs and consumer-facing non-invasive neurotechnology.',
    funding: [
      { company: 'Neuralink', amount: '$650M', round: 'Series D', focus: 'Intracortical BCI, Blindsight' },
      { company: 'Merge Labs', amount: '$252M', round: 'Series A', focus: 'Ultrasound-based BCI' },
      { company: 'Science Corporation', amount: '$230M', round: 'Series B', focus: 'PRIMA retinal implant' },
      { company: 'Synchron', amount: '$200M', round: 'Series C', focus: 'Endovascular Stentrode' },
    ],
    milestones2026: [
      'Synchron pivotal trial enrollment expected to begin (targeting FDA PMA by 2028)',
      'Neuralink PRIME study targeting 30-patient enrollment milestone',
      'Science Corporation CE mark approval for PRIMA retinal implant in Europe',
      'FDA guidance on adaptive neurostimulation — implications for closed-loop BCIs',
      'Neuralink Blindsight visual prosthesis first-in-human implant',
      'Paradromics Connect-One first chronic speech restoration BCI implant',
      'Potential IPO activity: NeuroPace, Synchron, or Neuralink could pursue public markets',
    ],
  },

  // ── Section 8: Neural Rights & Ethics ───────
  ethics: {
    title: 'Neural Rights, Ethics & Cognitive Privacy',
    subtitle: 'As BCIs decode thoughts and intentions, neural data rights, mental privacy, and cognitive liberty are emerging as critical ethical and regulatory frontiers.',
    concerns: [
      { title: 'Mental Privacy', desc: 'Who has access to your neural data? Can brain signals be subpoenaed? Neural data rights legislation emerging globally as a critical regulatory frontier.' },
      { title: 'Cognitive Liberty', desc: 'The right to mental self-determination. Should BCIs be used for cognitive enhancement in healthy individuals? Where is the line between therapy and augmentation?' },
      { title: 'Algorithmic Bias', desc: 'AI neural decoders trained on limited populations may perform poorly for underrepresented groups. Bias in training data could create unequal BCI access.' },
      { title: 'Identity & Agency', desc: 'If a BCI influences behavior through stimulation, who is responsible for the action? Questions of agency when closed-loop systems modify neural activity.' },
      { title: 'Data Security', desc: 'Neural data is the most intimate data possible. Hacking a BCI could mean reading or manipulating thoughts. Security standards are nascent.' },
      { title: 'Equity & Access', desc: 'BCIs cost $50K–$200K+. Will cognitive enhancement be available only to the wealthy? Risk of creating neuro-inequality divide.' },
    ],
  },

  // ── Section 9: Technology Pipeline ──────────
  techPipeline: {
    title: 'BCI Technology Pipeline: What\'s Coming 2026–2030',
    subtitle: 'Higher channel counts, bidirectional systems, wireless implants, and AI-native architectures — the next generation of brain-computer interfaces.',
    near: [
      { title: '3,000-Electrode Next-Gen Neuralink', desc: 'Neuralink developing next-generation device with 3× the electrode count of current N1 implant. Richer brain signals for more complex control.' },
      { title: 'Wireless & Fully Implantable', desc: 'Wireless charging and fully implantable BCI systems becoming standard. No percutaneous connectors — reduced infection risk.' },
      { title: 'Ultrasound-Based BCI', desc: 'Merge Labs developing ultrasound-based brain reading — potentially non-invasive with high spatial resolution. First technical demonstrations expected.' },
      { title: '10,000-Electrode Neuralace', desc: 'Neuralink Neuralace in R&D — 10,000 electrodes for whole-brain scale recording. Orders of magnitude beyond current systems.' },
    ],
    mid: [
      'Bidirectional BCIs: Not just reading from but writing to the brain (sensory feedback)',
      'Real-time natural-speed speech restoration for paralyzed patients',
      'Cortical implants for blindness restoration (Blindsight, PRIMA)',
      'Memory BCIs: Hippocampal prosthetics for memory impairment (very early stage)',
      'Closed-loop neurostimulation for depression, PTSD, and addiction',
    ],
    far: [
      'Whole-brain recording: Millions of simultaneous neural recordings',
      'Cognitive enhancement: BCIs that augment memory, attention, or processing speed',
      'Brain-to-brain communication: Direct neural communication between individuals',
      'Consumer-grade silent speech interfaces — dictation without vocalizing',
      'Integration with AR/VR for immersive neural-haptic experiences',
    ],
  },

  // ── Section 10: China & Global Race ─────────
  globalRace: {
    title: 'The Global BCI Race: US, China & Europe',
    subtitle: 'China approved the world\'s first commercial invasive BCI. The US leads in VC funding and clinical trials. Europe advances with regulatory frameworks.',
    regions: [
      { name: 'United States', position: 'Innovation Leader', desc: 'Neuralink, Synchron, Paradromics, Precision Neuroscience. Strongest VC funding. FDA breakthrough device designations accelerating approvals. 21+ implants across 4 nations.' },
      { name: 'China', position: 'First Commercial Approval', desc: 'Neuracle NEO — world\'s first approved invasive BCI beyond clinical trials. BCI listed in China\'s five-year plan as key industry alongside quantum, humanoid robots. Incorporated into health insurance.' },
      { name: 'Europe', position: 'Regulatory Pioneer', desc: 'Science Corporation PRIMA seeking CE mark. Strong academic research base. EU AI Act implications for neural decoding algorithms. ONWARD Medical ARC-BCI expanding enrollment.' },
      { name: 'Australia', position: 'Clinical Trial Hub', desc: 'Synchron originated in Australia. Active BCI trial region. Government investment programs supporting neurotechnology research and development.' },
    ],
  },

  // ── Section 11: Future Outlook ──────────────
  futureOutlook: {
    title: 'BCI 2026–2030: What to Expect',
    subtitle: 'The next four years will determine whether BCIs move from clinical tools to accessible medical and consumer devices — and whether neural rights legislation keeps pace.',
    predictions: [
      { year: '2026', prediction: 'Neuralink Blindsight first-in-human', detail: 'Paradromics Connect-One chronic implant. BCI market crosses $3.5B. Non-invasive consumer EEG OEM partnerships expand.' },
      { year: '2027', prediction: 'FDA guidance on adaptive neurostimulation finalized', detail: 'Closed-loop BCIs for depression enter pivotal trials. First bidirectional BCI with sensory feedback in humans.' },
      { year: '2028', prediction: 'Synchron FDA PMA approval — first commercial endovascular BCI in US', detail: 'Speech BCIs achieving natural-speed communication (100+ WPM). Potential BCI IPO activity.' },
      { year: '2029', prediction: '10,000-electrode BCIs entering clinical trials', detail: 'Neural rights legislation passed in multiple jurisdictions. Consumer EEG achieving real-time silent speech interfaces.' },
      { year: '2030', prediction: 'BCI market reaches $6–12B', detail: 'FDA-approved thought-based communication for ALS. First cognitive enhancement applications begin clinical testing. Consumer-grade BCI devices mainstream.' },
    ],
  },

  // ── Section 12: FAQ ─────────────────────────
  faq: {
    title: 'Brain-Computer Interface Frequently Asked Questions',
    subtitle: 'Structured answers to the most searched BCI questions — optimized for AI search engines and rich snippets.',
    items: [
      { q: 'What is a brain-computer interface?', a: 'A brain-computer interface (BCI) is a system that records electrical, chemical, or optical signals from neural tissue and translates them into digital commands, while optionally delivering stimulation back to the brain. Modern BCI systems integrate AI-based signal decoders, wireless transmission, and edge computing for real-time human-machine interaction. BCIs can be invasive (requiring surgery) or non-invasive (using scalp electrodes).' },
      { q: 'How does Neuralink work?', a: 'Neuralink\'s N1 Implant uses 1,024 ultra-thin electrode threads — each thinner than a human hair — implanted directly into the motor cortex to record neural signals. A surgical robot inserts the threads with micron precision. The signals are wirelessly transmitted to an external device where AI algorithms decode the user\'s intentions into digital actions like cursor control. As of 2026, 21 patients have been implanted across 4 nations. Neuralink is also developing Blindsight, a cortical visual prosthesis to restore vision.' },
      { q: 'What is the difference between invasive and non-invasive BCI?', a: 'Invasive BCIs require surgery to implant electrodes directly on or in the brain, offering high signal fidelity and single-neuron resolution but carrying surgical risks. Non-invasive BCIs use scalp-mounted EEG electrodes, requiring no surgery but providing lower signal quality attenuated by the skull. Invasive BCIs are used for clinical applications like paralysis and ALS, while non-invasive BCIs serve consumer markets like gaming, focus monitoring, and meditation. AI-based spatial filtering is helping close the quality gap for non-invasive systems.' },
      { q: 'How fast can BCI speech decoding work?', a: 'The current record for BCI speech decoding is 62 words per minute, achieved by Stanford/BrainGate using intracortical electrodes and transformer-based AI decoders. This approaches the natural speech rate of ~150 WPM. UCSF researchers have decoded full sentences from a paralyzed ALS patient. BrainGate also decoded imagined handwriting at 90 characters per minute with 94% accuracy. By 2028, speech BCIs are expected to achieve natural-speed communication.' },
      { q: 'How big is the BCI market?', a: 'The global brain-computer interface market was valued at approximately $2.8 billion in 2025 and is estimated at $3.2 billion in 2026. Projections from Grand View Research, MarketsandMarkets, and Global Market Insights put the market at $6–12 billion by 2030, representing a 15–18% CAGR. The fastest-growing segments are clinical-stage implantable communication BCIs and non-invasive consumer EEG devices. Deep brain stimulation currently constitutes the largest segment by revenue.' },
      { q: 'Are brain-computer interfaces safe?', a: 'Invasive BCIs carry surgical risks including hemorrhage, infection, and glial scarring that can degrade signals over time. However, newer approaches like Synchron\'s endovascular Stentrode avoid open brain surgery by inserting devices through blood vessels. China\'s NEO device was approved partly because its epi-cortical design presents lower risk than penetrating implants. Non-invasive BCIs have no surgical risk. The FDA has granted breakthrough device designations to several BCI systems, and over 4,000 patients have been safely implanted with NeuroPace RNS for epilepsy.' },
      { q: 'What is Synchron\'s Stentrode and how is it different from Neuralink?', a: 'Synchron\'s Stentrode is an endovascular BCI implanted through the blood vessels — no open brain surgery required. A catheter inserts the device into a blood vessel on the surface of the motor cortex. This approach dramatically reduces surgical risk compared to Neuralink\'s craniotomy-based implant. Synchron has FDA breakthrough device designation and has implanted patients in the US and Australia. The trade-off is lower electrode count (16 contacts vs Neuralink\'s 1,024), but the safety profile makes it the leading candidate for first commercial BCI approval in the US.' },
      { q: 'What are neural rights?', a: 'Neural rights are legal protections for cognitive liberty, mental privacy, and mental integrity in the era of neurotechnology. Chile became the first country to amend its constitution to include neural rights in 2021. The US states of Colorado and Minnesota have passed neural privacy legislation. The concern is that BCIs could eventually allow third parties to access or manipulate neural data. The NeuroRights Foundation advocates for five fundamental neural rights: cognitive liberty, mental privacy, mental integrity, psychological continuity, and fair access.' },
    ],
  },

  // ── SEO Keywords ────────────────────────────
  seoKeywords: {
    primary: ['brain-computer interface', 'BCI', 'Neuralink', 'neural implant', 'EEG headset', 'brain chips'],
    secondary: ['neural decoding', 'neurotechnology', 'brain-computer interface companies', 'non-invasive BCI', 'neural signals', 'cognitive enhancement'],
    longTail: [
      'how does Neuralink brain chip work',
      'brain computer interface clinical trials 2026',
      'non-invasive EEG headset for gaming',
      'BCI speech decoding words per minute',
      'neural implant FDA approval timeline',
      'brain computer interface market size 2030',
      'neural rights and cognitive privacy',
    ],
  },
};
